Medivolve Inc. MEDVF
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 295.93% | -30.22% | -44.07% | -97.97% | -99.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 295.93% | -30.22% | -44.07% | -97.97% | -99.59% |
| Cost of Revenue | -25.00% | 2,308.33% | -60.19% | -103.03% | -99.68% |
| Gross Profit | 592.88% | -40.67% | -35.20% | -91.65% | -99.45% |
| SG&A Expenses | -30.02% | -65.72% | -13.04% | -81.52% | -87.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.86% | -63.96% | -16.46% | -87.37% | -94.32% |
| Operating Income | 53.50% | 70.68% | 9.38% | 77.20% | 17.48% |
| Income Before Tax | 58.73% | 76.32% | 47.56% | 83.46% | -19.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.73% | 76.32% | 47.56% | 73.24% | -4.45% |
| Earnings from Discontinued Operations | 73.61% | -350.46% | 49.80% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.89% | -109.77% | 51.02% | 73.24% | -89.81% |
| EBIT | 53.50% | 70.68% | 9.38% | 77.20% | 17.48% |
| EBITDA | 48.70% | 71.90% | -143.60% | 77.21% | 21.74% |
| EPS Basic | 67.88% | -109.76% | 51.04% | 73.23% | -89.76% |
| Normalized Basic EPS | 54.10% | 77.17% | 30.07% | 76.87% | 21.12% |
| EPS Diluted | 68.08% | -109.76% | 49.52% | 73.23% | -90.95% |
| Normalized Diluted EPS | 54.10% | 77.17% | 30.07% | 76.87% | 21.12% |
| Average Basic Shares Outstanding | 0.00% | 0.04% | 0.00% | 0.00% | 0.01% |
| Average Diluted Shares Outstanding | 0.00% | 0.04% | 0.00% | 0.00% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |